Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Hydralazine Valproate for Ovarian Cancer

The recruitment status of this study is unknown because the information has not been verified recently.
Verified August 2007 by National Institute of Cancerología.
Recruitment status was  Recruiting
Information provided by:
National Institute of Cancerología Identifier:
First received: September 19, 2007
Last updated: September 20, 2007
Last verified: August 2007

The current standard for recurrent, persistent or metastatic cisplatin-resistant ovarian cancer is palliative chemotherapy with either topotecan, liposomal doxorubicin or gemcitabine, however, the results need to be improved. Epigenetic aberrations play an important role in cancer progression by silencing growth regulatory genes and there is now evidence that inhibitors of DNA methylation and HDAC inhibition synergize the cytotoxicity of chemotherapy.

Objective. To determine the superiority of epigenetic therapy with hydralazine and valproate plus topotecan over placebo plus topotecan upon progression-free survival.

Hypothesis. Hydralazine and magnesium valproate associated to topotecan will increase progression-free survival from 6 to 9 months as compared with the same regimen of chemotherapy plus placebo.

Condition Intervention Phase
Ovarian Cancer
Drug: Hydralazine and magnesium valproate
Drug: Placebo
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Randomized, Double-Blind, Phase III Trial of Chemotherapy Plus the Transcriptional Therapy Hydralazine and Magnesium Valproate Versus Chemotherapy Plus Placebo in Cisplatin-Resistant Recurrent Ovarian Cancer.

Resource links provided by NLM:

Further study details as provided by National Institute of Cancerología:

Primary Outcome Measures:
  • Progression-Free Survival [ Time Frame: 2-years ]

Secondary Outcome Measures:
  • Safety, response, overall survival. [ Time Frame: 2-years ]

Estimated Enrollment: 211
Study Start Date: August 2007
Estimated Study Completion Date: December 2009
Arms Assigned Interventions
Experimental: 1
Topotecan hydralazine valproate
Drug: Hydralazine and magnesium valproate
Hydralazine and valproate will start from seven days before day 1 of chemotherapy until the end of the sixth course. Hydralazine will be administered at 182mg (rapid) or 83mg (slow) according to the acetylator phenotype in a single daily dose and magnesium valproate at an oral dose of 40mg/Kg t.i.d.
Placebo Comparator: 2
Placebo, hydralazine, valproate
Drug: Placebo
Placebos will start from seven days before day 1 of chemotherapy until the end of the sixth course. Placebo tablets will be administered in an identical form that experimental drugs.

Detailed Description:

Randomized, double-blind phase III trial. A total of 211 patients (alpha 0.5, power 0.8)with cisplatin-resistant recurrent or persistent cancer will be randomized to topotecan + placebo or topotecan + hydralazine + valproate for 6 courses every 4 weeks. Patients will receive an oral dose of hydralazine of 182mg (rapid) or 83mg (slow) according to the acetylator phenotype in a single daily dose and magnesium valproate at an oral dose of 40mg/Kg t.i.d. Both drugs in a slow-release formulation. Experimental drugs or placebo will start from seven days before day 1 of chemotherapy until the end of the sixth course.


Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Female
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Measurable or evaluable disease(evaluable according to CA125 criteria of GCIG) Cisplatin resistant ovarian cancer
  • Persistent or progression to first line platinum-based chemotherapy
  • Relapse within 6 months after completing first line platinum-based chemotherapy
  • Platinum-sensitive disease who are failed to second line therapy based on platinum.
  • Adequate organic function as defined by: hemoglobin >10 g/L, leukocytes >4000/mm3, platelets >100 000mm3; normal creatinine value and creatinine clearance >60 mL/min; total bilirubin < 1.5 upper normal limit value

Exclusion Criteria:

  • History of allergy to hydralazine or valproate;
  • Past or present condition of rheumatic disease, central nervous system disease, heart failure from aortic stenosis and postural hypotension as diagnosed by a physician;
  • Newly diagnosed hypertension patients with or without pharmacological treatment are allowed as long as their treatment do not include hydralazine.
  • Previous use of the experimental drugs (hydralazine and magnesium valproate) as well as if patients were pregnant or breast-feeding.

Other exclusion criteria are uncontrolled systemic disease or infection.

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00533299

Contact: Alfonso Dueñas-Gonzalez, MD PhD +5255 56280486

Instituto Nacional de Cancerologia Recruiting
Mexico City, Tlalpan, Mexico, 14080
Principal Investigator: Dolores Gallardo, MD         
Sponsors and Collaborators
National Institute of Cancerología
Principal Investigator: Dolores Gallardo, MD Instituto Nacional de Cancerologia, Columbia
  More Information

No publications provided Identifier: NCT00533299     History of Changes
Other Study ID Numbers: 006/028/DDI
Study First Received: September 19, 2007
Last Updated: September 20, 2007
Health Authority: Mexico: Ethics Committee

Keywords provided by National Institute of Cancerología:
Epigenetics, hydralazine, valproate, ovarian cancer

Additional relevant MeSH terms:
Ovarian Neoplasms
Adnexal Diseases
Endocrine Gland Neoplasms
Endocrine System Diseases
Genital Diseases, Female
Genital Neoplasms, Female
Gonadal Disorders
Neoplasms by Site
Ovarian Diseases
Urogenital Neoplasms
Valproic Acid
Antihypertensive Agents
Antimanic Agents
Cardiovascular Agents
Central Nervous System Agents
Central Nervous System Depressants
Enzyme Inhibitors
GABA Agents
Molecular Mechanisms of Pharmacological Action
Neurotransmitter Agents
Pharmacologic Actions
Physiological Effects of Drugs
Psychotropic Drugs
Therapeutic Uses
Tranquilizing Agents
Vasodilator Agents processed this record on November 25, 2014